These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34222869)

  • 1. Kinetics of tau aggregation reveals patient-specific tau characteristics among Alzheimer's cases.
    Kamath TV; Klickstein N; Commins C; Fernandes AR; Oakley DH; Frosch MP; Hyman BT; Dujardin S
    Brain Commun; 2021; 3(2):fcab096. PubMed ID: 34222869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons.
    Oakley DH; Klickstein N; Commins C; Chung M; Dujardin S; Bennett RE; Hyman BT; Frosch MP
    J Neurosci; 2021 May; 41(19):4335-4348. PubMed ID: 33893219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteopathic tau seeding predicts tauopathy in vivo.
    Holmes BB; Furman JL; Mahan TE; Yamasaki TR; Mirbaha H; Eades WC; Belaygorod L; Cairns NJ; Holtzman DM; Diamond MI
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):E4376-85. PubMed ID: 25261551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human tauopathy-derived tau strains determine the substrates recruited for templated amplification.
    Tarutani A; Miyata H; Nonaka T; Hasegawa K; Yoshida M; Saito Y; Murayama S; Robinson AC; Mann DMA; Tomita T; Hasegawa M
    Brain; 2021 Sep; 144(8):2333-2348. PubMed ID: 33693528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
    Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
    Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease brain contains tau fractions with differential prion-like activities.
    Li L; Shi R; Gu J; Tung YC; Zhou Y; Zhou D; Wu R; Chu D; Jin N; Deng K; Xu J; Gong CX; Iqbal K; Liu F
    Acta Neuropathol Commun; 2021 Feb; 9(1):28. PubMed ID: 33597014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based inhibitors halt prion-like seeding by Alzheimer's disease-and tauopathy-derived brain tissue samples.
    Seidler PM; Boyer DR; Murray KA; Yang TP; Bentzel M; Sawaya MR; Rosenberg G; Cascio D; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Eisenberg DS
    J Biol Chem; 2019 Nov; 294(44):16451-16464. PubMed ID: 31537646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trans-seeding of Alzheimer-related tau protein by a yeast prion.
    Flach M; Leu C; Martinisi A; Skachokova Z; Frank S; Tolnay M; Stahlberg H; Winkler DT
    Alzheimers Dement; 2022 Dec; 18(12):2481-2492. PubMed ID: 35142027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
    Sydow A; Mandelkow EM
    Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain.
    Narasimhan S; Guo JL; Changolkar L; Stieber A; McBride JD; Silva LV; He Z; Zhang B; Gathagan RJ; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Nov; 37(47):11406-11423. PubMed ID: 29054878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two simple assays for assessing the seeding activity of proteopathic tau.
    Liu F; Wu R; Jin N; Chu D; Gu J; Tung YC; Hu Z; Gong CX; Iqbal K
    Front Aging Neurosci; 2023; 15():1073774. PubMed ID: 37091523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformation determines the seeding potencies of native and recombinant Tau aggregates.
    Falcon B; Cavallini A; Angers R; Glover S; Murray TK; Barnham L; Jackson S; O'Neill MJ; Isaacs AM; Hutton ML; Szekeres PG; Goedert M; Bose S
    J Biol Chem; 2015 Jan; 290(2):1049-65. PubMed ID: 25406315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy.
    Colin M; Dujardin S; Schraen-Maschke S; Meno-Tetang G; Duyckaerts C; Courade JP; Buée L
    Acta Neuropathol; 2020 Jan; 139(1):3-25. PubMed ID: 31686182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry.
    Furman JL; Holmes BB; Diamond MI
    J Vis Exp; 2015 Dec; (106):e53205. PubMed ID: 26710240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau.
    Jackson SJ; Kerridge C; Cooper J; Cavallini A; Falcon B; Cella CV; Landi A; Szekeres PG; Murray TK; Ahmed Z; Goedert M; Hutton M; O'Neill MJ; Bose S
    J Neurosci; 2016 Jan; 36(3):762-72. PubMed ID: 26791207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils.
    Marreiro A; Van Kolen K; Sousa C; Temmerman L; Vasconcelos B; Crespo-Rodriguez R; van Weering JRT; Van Dam D; De Deyn PP; Apetri A; Schoofs L; Mercken MH
    BMC Mol Cell Biol; 2020 Nov; 21(1):81. PubMed ID: 33183222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving prion-like tau conformers differentially alter postsynaptic proteins in neurons inoculated with distinct isolates of Alzheimer's disease tau.
    Hromadkova L; Kim C; Haldiman T; Peng L; Zhu X; Cohen M; de Silva R; Safar JG
    Cell Biosci; 2023 Sep; 13(1):174. PubMed ID: 37723591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain.
    DeVos SL; Corjuc BT; Oakley DH; Nobuhara CK; Bannon RN; Chase A; Commins C; Gonzalez JA; Dooley PM; Frosch MP; Hyman BT
    Front Neurosci; 2018; 12():267. PubMed ID: 29740275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau antibody 77G7 targeting microtubule binding domain suppresses proteopathic tau to seed tau aggregation.
    Li L; Miao J; Chu D; Jin N; Tung YC; Dai CL; Hu W; Gong CX; Iqbal K; Liu F
    CNS Neurosci Ther; 2022 Dec; 28(12):2245-2259. PubMed ID: 36114722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding.
    Soares AC; Ferreira A; Mariën J; Delay C; Lee E; Trojanowski JQ; Moechars D; Annaert W; De Muynck L
    J Biol Chem; 2021; 296():100636. PubMed ID: 33831417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.